comparemela.com

Latest Breaking News On - Preliminary safety results - Page 1 : comparemela.com

Neurogene : ASGCT NGN-401 Clinical Safety Poster

Preliminary Safety Results from the Ph1/2 Study of NGN-401, a Novel Regulated Gene Therapy for Rett Syndrome Suter B1, Lieberman D2, Benke T3,.

United statesNew yorkBaylor college of medicineMonroe carell jrNeurogene incDepartment of pediatricsHarvard medical schoolAmerican society of geneDepartment of pediatrics neurologyVanderbilt university medical centerUniversity of colorado school medicineDepartment of neurologyPreliminary safety resultsNovel regulated gene therapyRett syndromeTexas children

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

NGN-401 has been generally well-tolerated by three patients with multiple months of follow-up .

United statesUnited kingdomRachel mcminnNeurogene incCompany annual report on formAmerican society for geneExchange commissionAmerican societyCell therapyChief executive officerPoster presentationPreliminary safety resultsNovel regulated gene therapyRett syndromeExhibit hallPrivate securities litigation reform act

Data from Incyte s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 (EHA2022) Congress (June

United statesHong kongUnited kingdomPonatinib iclusigCatalina lovemanSteven steinBendamustine rituximabThrombocythemia myelofibrosisRuxolitinib jakafiChristine chiouBendamustine obinutuzumabTafasitamab monjuviXencor incDrug administrationEuropean hematology associationTakeda pharmaceutical company

vimarsana © 2020. All Rights Reserved.